Detection of bone marrow metastases by FDG-PET/CT in patients with rhabdomyosarcoma
M
Marissa Just
Primary Investigator
Enrolling By Invitation
40 years and younger
All
Phase
N/A
1 participants needed
2 Locations
Brief description of study
What is this study about?
The purpose of this study is to confirm >92% sensitivity and specificity of FDG-PET/CT
imaging in detecting bone marrow involvement in RMS (using bone marrow
biopsies/ aspirates as the gold standard) and to show that reassignment of bone marrow status by
FDG-PET/CT does not result in a change in management for patients with
PET positive/biopsy negative or PET negative/biopsy positive bone marrowus.
This is a retrospective review of pediatric rhabdomyosarcoma patients
who had diagnostic staging studies performed at Riley Children’s
Hospital. This will also survey practitioners on their practice as
related to pediatric rhabdomyosarcoma.
This is a survey that will be distributed by the research team on MEMBER only websites for the pediatric and young adult oncology community (students, fellows, residents, advanced practice providers, faculty, etc.), so it will not be open to the general public.
THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office
Email: iutrials@iu.edu
Phone: (317) 278-5632
Detailed description of study
What happens during study participation?
- This survey will be posted and open to all who are members of the pediatric oncology/young adult community. There will be a link to the survey sent via message boards that are part of member only oncology society websites.
- It will go out to the distribution list for the American Society for Pediatric Hematology/Oncology (ASPHO), the Connective Tissue Oncology Society (CTOS) and also to similar groups in Europe and Asia.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Rhabdomyosarcoma, Riley
-
Age: - 40 Years
-
Gender: All
Inclusion criteria
- First diagnosis of rhabdomyosarcoma
- Age 0-40 years
- FDG-PET/CT performed before start of chemotherapy at first diagnosis and reports available
- Bone marrow assessment performed before start of chemotherapy at first diagnosis and reports available
- Children, adolescents and adults diagnosed with RMS at individual COG, CWS and EpSSG institutions.
Exclusion criteria
- Administration of chemotherapy prior to FDG-PET/CT or bone marrow assessment
Updated on
13 Sep 2024.
Study ID: PHO-IIR-FRIENDSHIP-PROJECT, 20141
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
